Bibliography
- Puri A , LoomisK, SmithB: Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic.Curr. Rev. Ther. Drug Carrier Syst.26(6), 523–580 (2009).
- Davis ME , ChenZG, ShinDM: Nanoparticle therapeutics. an emerging treatment modality for cancer.Nat. Rev. Drug Discov.7(9), 771–782 (2008).
- Fenske DB , CullisPR: Liposomal nanomedicines.Expert Opin. Drug Deliv.5(1), 25–44 (2008).
- Fenske DB , ChonnA, CullisPR: Liposomal nanomedicines: an emerging field.Toxicol. Pathol.36(1), 21–29 (2008).
- Marczak A , Wrzesie?-Ku?A, KrykowskiE, RobakT, Jú?wiakZ: The interaction of daunorubicin and mitoxantrone with the red blood cells of acute myeloid leukemia patients.Cell Mol. Biol. Lett.8(4), 885–890 (2003).
- Simeonova M , IvanovaG, EnchevVet al.: Physicochemical characterization and in vitro behavior of daunorubicin-loaded poly(butylcyanoacrylate) nanoparticles.Acta Biomater.5(6), 2109–2121 (2009).
- Weiss RB : The anthracyclines: will we ever find a better doxorubicin?Semin. Oncol.19(6), 670–686 (1992).
- Rabbani A , FinnRM, AusióJ: The anthracycline antibiotics: antitumor drugs that alter chromatin structure.Bioessays27(1), 50–56 (2005).
- Minotti G , MennaP, SalvatorelliE, CairoG, GianniL: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.Pharmacol. Rev.56(2), 185–229 (2004).
- Lotfi K , ZackrissonAL, PetersonC: Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance.Cancer Lett.178(2), 141–149 (2002).
- Zucchi R , DanesiR: Cardiac toxicity of antineoplastic anthracyclines.Curr. Med. Chem. Anticancer Agents.3(2), 151–171 (2003).
- Endicott JA , LingV: The biochemistry of P-glycoprotein-mediated multidrug resistance.Annu. Rev. Biochem.58, 137–171 (1989).
- Dean M , FojoT, BatesS: Tumour stem cells and drug resistance.Nat. Rev. Cancer.5(4), 275–284 (2005).
- Gabizon AA : Liposomal anthracyclines.Hematol. Oncol. Clin. North Am.8, 431–450 (1994).
- Lasic DD : Liposomes: From Physics to Applications. Elsevier Science, Amsterdam, The Netherlands, 575 (1993).
- Cowens JW , CreavenPJ, GrecoWRet al.: Initial clinical (Phase I) trial of Myocet (doxorubicin encapsulated in liposomes).Cancer Res.53, 2796–2802 (1993).
- Batist G , RamakrishnanG, RaoCSet al.: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.J. Clin. Oncol.19, 1444–1454 (2001).
- Tulpule A , EspinaBM, BermanNet al.: Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin‘s lymphoma.Clin. Lymphoma. Myeloma.7(1), 59–64 (2006).
- Luminari S , MontaniniA, CaballeroDet al.: Nonpegylated liposomal doxorubicin (Myocet™) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the Phase II EUR018 trial.Ann. Oncol.21(7), 1492–1499 (2010).
- Visani G , IsidoriA: Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin‘s lymphoma: where we stand.Expert Rev. Anticancer Ther.9(3), 357–363 (2009).
- Visani G , FerraraF, AlesianiFet al.: R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study.Leuk. Lymphoma.49(6), 1081–1086 (2008).
- Soloman R , GabizonAA: Clinical pharmacology of liposomal anthracyclines: focus on PEGylated liposomal Doxorubicin.Clin. Lymphoma Myeloma.8(1), 21–32 (2008).
- Martino R , PereaG, CaballeroMDet al.: Cyclophosphamide, PEGylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective Phase II study.Haematologica87, 822–827 (2002).
- Visani G , GuiducciB, D‘AdamoFet al.: Cyclophosphamide, PEGylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin‘s lymphoma.Leuk. Lymphoma46(3), 477–479 (2005).
- Wollina U , DummerR, BrockmeyerNHet al.: Multicenter study of PEGylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma.Cancer98, 993–1001 (2003).
- Rifkin RM , GregorySA, MohrbacherAet al.: PEGylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.Cancer106, 848–858 (2006).
- Muthu MS , FengSS: Nanopharmacology of liposomes developed for cancer therapy.Nanomedicine5(7), 1017–1019 (2010).